Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist

Circulation Research

Volumn 94, Issue 11, 2004, Pages 1451-1457

  Lochard, Nadheige ^a   Thibault, Gaétan ^a   Silversides, David W ^b   Touyz, Rhian M ^a   Reudelhuber, Timothy L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Angiotensin IV; Brain renin angiotensin system; Hypertension; Transgenic model

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ANGIOTENSIN II [3-8]; ANGIOTENSIN IV [1 ALANINE 5 GLYCINE]; ANGIOTENSIN IV [5 GLYCINE]; CALCIUM ION; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IODINE 125; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; CALCIUM CELL LEVEL; CONTROLLED STUDY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; TRANSGENIC MOUSE;

1-SARCOSINE-8-ISOLEUCINE ANGIOTENSIN II; ALLOSTERIC REGULATION; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BRAIN; CALCIUM SIGNALING; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION; GENES, SYNTHETIC; GLIAL FIBRILLARY ACIDIC PROTEIN; GLOBINS; HUMANS; HYPERTENSION; IMIDAZOLES; MICE; MICE, TRANSGENIC; ORGAN SPECIFICITY; PROTEIN SORTING SIGNALS; PYRIDINES; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECOMBINANT FUSION PROTEINS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TRANSGENES;

EID: 2942659879     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000130654.56599.40     Document Type: Article

References (39)

1. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22(Suppl 4):S1-S14.
2. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236.
3. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993;268:24539-24542.
4. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med. 2001;79:76-102.
5. Ganten D, Hermann K, Bayer C, Unger T, Lang RE. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983;221:869-871.
6. Kubo T, Yamaguchi H, Tsujimura M, Hagiwara Y, Fukumori R. An angiotensin system in the anterior hypothalamic area anterior is involved in the maintenance of hypertension in spontaneously hypertensive rats. Brain Res Bull. 2000;52:291-296.
7. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev. 1992;13:329-380.
8. Moeller I, Allen AM, Chai SY, Zhuo J, Mendelsohn FA. Bioactive angiotensin peptides. J Hum Hypertens. 1998;12:289-293.
9. Wright JW, Morseth SL, Abhold RH, Harding JW. Pressor action and dipsogenicity induced by angiotensin II and III in rats. Am J Physiol. 1985;249:R514-R521.
10. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A. 1999;96:13415-13420.
11. Harding JW, Cook VI, Miller-Wing AV, Hanesworth JM, Sardinia MF, Hall KL, Stobb JW, Swanson GN, Coleman JK, Wright JW. Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. Brain Res. 1992;583:340-343.
12. Wright JW, Harding JW. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev. 1997;25:96-124.
13. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001;276:48623-48626.
14. Braszko JJ, WLasienko J, Kupryszewski G, Witczuk B, Wisniewski K. Behavioral effects of angiotensin II and angiotensin II-(4-8)-pentapeptide in rats. Physiol Behav. 1988;44:327-332.
15. Wright JW, Krebs LT, Stobb JW, Harding JW. The angiotensin IV system: functional implications. Front Neuroendocrinol. 1995;16:23-52.
16. Li YD, Block ER, Patel JM. Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation. Am J Physiol Lung Cell Mol Physiol. 2002;283:L707-L716.
17. Mustafa T, Lee JH, Chai SY, Albiston AL, McDowall SG, Mendelsohn FA. Bioactive angiotensin peptides: focus on angiotensin IV. J Renin Angiotensin Aldosterone Syst. 2001;2:205-210.
18. Methot D, van Kats JP, Lochard N, Tremblay F, Silversides DW, Reudelhuber TL. Development and application of a biological peptide pump for the study of the in vivo actions of angiotensin peptides. Am J Hypertens. 2001;14:38S-43S.
19. Lochard N, Silversides DW, van Kats JP, Mercure C, Reudelhuber TL. Brain-specific restoration of angiotensin II corrects renal defects seen in angiotensinogen-deficient mice. J Biol Chem. 2003;278:2184-2189.
20. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci. 1994;14:1030-1037.
21. Methot D, Reudelhuber TL, Silversides DW. Evaluation of tyrosinase minigene co-injection as a marker for genetic manipulations in transgenic mice. Nucleic Acids Res. 1995;23:4551-4556.
22. Harlow E, Lane D. Antibodies: A laboratory manual. Cold Spring Harbor Laboratory Press; 1988.
23. van Kats JP, Methot D, Paradis P, Silversides DW, Reudelhuber TL. Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart. J Biol Chem. 2001;276:44012-44017.
24. Prescott G, Silversides DW, Chiu SM, Reudelhuber TL. Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. Physiol Genomics. 2000;4:67-73.
25. Bennett JP, Jr., Snyder SH. Angiotensin II binding to mammalian brain membranes. J Biol Chem. 1976;251:7423-7430.
26. Touyz RM, Tolloczko B, Schiffrin EL. Mesenteric vascular smooth muscle cells from spontaneously hypertensive rats display increased calcium responses to angiotensin II but not to endothelin-1. J Hypertens. 1994;12:663-673.
27. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
28. Methot D, LaPointe MC, Touyz RM, Yang XP, Carretero OA, Deschepper CF, Schiffrin EL, Thibault G, Reudelhuber TL. Tissue targeting of angiotensin peptides. J Biol Chem. 1997;272:12994-12999.
29. Sardinia MF, Hanesworth JM, Krebs LT, Harding JW. AT4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides. 1993;14:949-954.
30. Gohlke P, Kox T, Jurgensen T, von Kugelgen S, Rascher W, Unger T, Culman J. Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:477-483.
31. Wright JW, Stubley L, Pederson ES, Kramar EA, Hanesworth JM, Harding JW. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci. 1999;19:3952-3961.
32. Fruitier-Arnaudin I, Cohen M, Bordenave S, Sannier F, Piot JM. Comparative effects of angiotensin IV and two hemorphins on angiotensin- converting enzyme activity. Peptides. 2002;23:1465-1470.
33. Wright JW, Sullivan MJ, Petersen EP, Harding JW. Brain angiotensin II and III binding and dipsogenicity in the rabbit. Brain Res. 1985;358:376-379.
34. Wright JW, Jensen LL, Roberts KA, Sardinia MF, Harding JW. Structure-function analyses of brain angiotensin control of pressor action in rats. Am J Physiol. 1989;257:R1551-R1557.
35. Wright JW, Bechtholt AJ, Chambers SL, Harding JW. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Peptides. 1996;17:1365-1371.
36. Krebs LT, Kramar EA, Hanesworth JM, Sardinia MF, Ball AE, Wright JW, Harding JW. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul Pept. 1996;67:123-130.
37. Champion HC, Czapla MA, Kadowitz PJ. Responses to angiotensin peptides are mediated by AT1 receptors in the rat. Am J Physiol. 1998;274: E115-E123.
38. Thomas WG, Qian H, Chang CS, Karnik S. Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem. 2000;275:2893-2900.
39. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, Vauquelin G. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem. 2002;277:23107-23110.